Pharming (PHAR) Other Non-Current Liabilities (2019 - 2021)

Pharming's (PHAR) quarterly Other Non-Current Liabilities came in at $1.9 million in Q2 2026, up 178.22% on a QoQ basis from $675000.0 in Q1 2026.

Analysis

Pharming (PHAR) Other Non-Current Liabilities (2019 - 2021) Analysis & Trends

Pharming (PHAR) has 5 years of Other Non-Current Liabilities data on file, last reported at $1.9 million in Q2 2026.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 million (changed N/A YoY) and the FY2025 annual result came in at $1.2 million, changed N/A from the prior year.
Other Non-Current Liabilities grew to $1.9 million in Q2 2026, from $675000.0 in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $1.9 million in Q2 2026 to a low of $675000.0 in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Pharming	794.84 Mn	635.34 Mn	141.47 Mn

Historic Data

Download Data